The international independent ranking organisation AD Scientific Index is more than an ordinary "Ranking". The "AD Scientific Index" analyses the academic work of scientists using the H-index, i10 index and number of citations, and provides results that can be used to evaluate the productivity and efficiency of individuals and institutions. In addition to ranking according to "total H-index" for individuals and institutions, you can also see the ranking and analyses according to "last 6 years H-index", "total i10 Productivity index", "last 6 years i10 Productivity index", "total citations" and "last 6 years citations" only in "AD Scientific Index". See also: Subject Rankings, University Subject Rankings and Universities Rankings 2024 (Sort by: Last 6 years H Index). Click here for individual or institutional registration.
AD Scientific Index - World Scientists Rankings - 2024 | H INDEX | i10 INDEX | CITATION | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
University / Institution |
Country | Region | World | Name | Country | University / Institution | Subject | Total | Last 6 year | Last 6 year/total | Total | Last 6 year | Last 6 year/total | Total | Last 6 year | Last 6 year/total |
126 | 121,670 | 137,513 | 419,342 |
|
United States | Pfizer Inc. |
Others
Influenza virus | Virology | Clinical Research | |
21 | 18 | 0.857 | 29 | 27 | 0.931 | 2,280 | 1,796 | 0.788 |
127 | 121,951 | 137,825 | 420,214 |
|
United States | Pfizer Inc. |
Others
Metabolism | Cardiovascular | |
21 | 18 | 0.857 | 25 | 23 | 0.920 | 2,235 | 947 | 0.424 |
128 | 122,082 | 137,975 | 420,534 |
|
United States | Pfizer Inc. |
Others
|
21 | 18 | 0.857 | 22 | 21 | 0.955 | 5,825 | 2,555 | 0.439 |
129 | 122,267 | 138,178 | 421,804 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
Clinical Pharmacology | PK/PD | Inflammation & Immunology | Infectious Diseases | |
21 | 17 | 0.810 | 34 | 26 | 0.765 | 2,708 | 2,233 | 0.825 |
130 | 122,516 | 138,451 | 422,758 |
|
United States | Pfizer Inc. |
Others
Rare Diseases | Friedreich ataxia | Gene therapy | Mitochondria | Drug discovery | |
21 | 17 | 0.810 | 29 | 23 | 0.793 | 2,624 | 1,103 | 0.420 |
131 | 123,452 | 139,510 | 426,504 |
|
United States | Pfizer Inc. |
Others
Metabolomics | Immunoaffinity enrichment LC-MS/MS | |
21 | 16 | 0.762 | 26 | 18 | 0.692 | 14,288 | 6,658 | 0.466 |
132 | 123,803 | 139,917 | 428,188 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Immunology
Cell Therapy | Immuno-oncology | Vaccine Development | |
21 | 15 | 0.714 | 34 | 22 | 0.647 | 1,428 | 708 | 0.496 |
133 | 124,486 | 140,702 | 431,191 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Neuroscience
Neuroscience | digital medicine | |
21 | 14 | 0.667 | 30 | 17 | 0.567 | 3,057 | 755 | 0.247 |
134 | 124,594 | 140,818 | 431,516 |
|
United States | Pfizer Inc. |
Others
NMR | Drug Discovery | |
21 | 14 | 0.667 | 28 | 19 | 0.679 | 1,705 | 911 | 0.534 |
135 | 125,036 | 141,315 | 433,497 |
|
United States | Pfizer Inc. |
Others
Biotherapeutics Translational Sciences | |
21 | 13 | 0.619 | 27 | 14 | 0.519 | 4,036 | 874 | 0.217 |
Click for INSTITUTIONAL BULK REGISTRATION and PREMIUM MEMBERSHIP advantages |
||||||||||||||||
136 | 126,422 | 142,849 | 438,599 |
|
United States | Pfizer Inc. |
Natural Sciences / Mathematical Sciences
Statistics | Biostatistics | Clinical Trials | Data Science | |
20 | 20 | 1.000 | 29 | 29 | 1.000 | 18,161 | 17,877 | 0.984 |
137 | 126,944 | 143,414 | 440,310 |
|
United States | Pfizer Inc. |
Others
|
20 | 19 | 0.950 | 41 | 34 | 0.829 | 1,324 | 870 | 0.657 |
138 | 127,517 | 144,062 | 442,707 |
|
United States | Pfizer Inc. |
Others
Biocatalysis | |
20 | 19 | 0.950 | 25 | 23 | 0.920 | 2,708 | 2,263 | 0.836 |
139 | 128,372 | 145,025 | 445,999 |
|
United States | Pfizer Inc. |
Others
Vaccines | |
20 | 18 | 0.900 | 27 | 23 | 0.852 | 1,376 | 852 | 0.619 |
140 | 128,458 | 145,114 | 446,219 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
Pharmacokinetics/pharmacodynamics | biotherapeutics | oncology | |
20 | 18 | 0.900 | 26 | 21 | 0.808 | 1,884 | 1,175 | 0.624 |
141 | 128,473 | 145,133 | 446,273 |
|
United States | Pfizer Inc. |
Others
Metabolomics | Proteomics | MALDI-Imaging | |
20 | 18 | 0.900 | 26 | 25 | 0.962 | 1,567 | 978 | 0.624 |
142 | 128,639 | 145,315 | 446,743 |
|
United States | Pfizer Inc. |
Others
Drug Safety | RNA Therapeutics | |
20 | 18 | 0.900 | 24 | 24 | 1.000 | 2,393 | 1,871 | 0.782 |
143 | 128,881 | 145,585 | 447,355 |
|
United States | Pfizer Inc. |
Others
|
20 | 18 | 0.900 | 21 | 20 | 0.952 | 1,123 | 753 | 0.671 |
144 | 130,056 | 146,922 | 452,922 |
|
United States | Pfizer Inc. |
Education / Education (Other, All)
formulation | drug delivery | biologics | |
20 | 16 | 0.800 | 30 | 22 | 0.733 | 4,147 | 1,709 | 0.412 |
145 | 130,632 | 147,569 | 454,712 |
|
United States | Pfizer Inc. |
Natural Sciences / Molecular Biology & Genetics
crispr | genetics | genomics | drug discovery | single-cell sequencing | |
20 | 16 | 0.800 | 22 | 19 | 0.864 | 9,204 | 4,745 | 0.516 |
146 | 130,894 | 147,856 | 456,236 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
Pharmacology | Drug Discovery | Medicinal Chemistry | Translational Research | Predictive Models | |
20 | 15 | 0.750 | 32 | 24 | 0.750 | 1,484 | 740 | 0.499 |
147 | 131,396 | 148,432 | 458,076 |
|
United States | Pfizer Inc. |
Medical and Health Sciences / Biophysics
Biophysics | Structural biology | Drug discovery & development | |
20 | 15 | 0.750 | 22 | 18 | 0.818 | 2,794 | 1,225 | 0.438 |
148 | 131,405 | 148,441 | 458,091 |
|
United States | Pfizer Inc. |
Others
|
20 | 15 | 0.750 | 22 | 19 | 0.864 | 2,213 | 1,085 | 0.490 |
149 | 131,723 | 148,802 | 460,026 |
|
United States | Pfizer Inc. |
Natural Sciences / Biological Science
GPCR | Membrane proteins | Antibodies | Structural Biology | SBDD | |
20 | 14 | 0.700 | 28 | 18 | 0.643 | 2,587 | 626 | 0.242 |
150 | 132,044 | 149,156 | 460,992 |
|
United States | Pfizer Inc. |
Natural Sciences / Chemical Sciences
Biotherapeutics | Mass Spectrometry | Glycosaminoglycans | Carbohydrates | LC-MS/MS | |
20 | 14 | 0.700 | 21 | 17 | 0.810 | 1,459 | 549 | 0.376 |